Kisho

ReCode Therapeutics, Inc. — Rare Disease Pipeline | Kisho

ReCode Therapeutics, Inc.

Other

Orphan Designations

0 approved, 2 designated

FDA Approvals

Active Trials

200 recruiting

Rare Diseases

across 6 areas

News (30d)

Quiet

ReCode Therapeutics, Inc. is a company with 2 orphan drug designations across 3 rare diseases. Active clinical trials in 2 indications. 1 active policy bill affects their portfolio.

Competitive Landscape

Diversified Portfolio

Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.

Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA

Approved: 0

In Trials: 2

Designated Only: 1

3 total diseases

Disease	Drug(s)	Stage
congenital heart disease	-	Des.TrialAppr.
cystic fibrosis	mRNA encoding full-length CFTR protein	Des.TrialAppr.
primary ciliary dyskinesia	DNAI1 mRNA encapsulated in a selective organ targeting lipid nanoparticle	Des.TrialAppr.